Global Anti-VEGT Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Anti-VEGT Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Anti-VEGF (Vascular Endothelial Growth Factor) drugs are a class of medications used to treat various eye conditions, particularly those affecting the retina and blood vessels at the back of the eye. VEGF is a protein that promotes the growth of new blood vessels. In certain eye diseases, excessive VEGF can contribute to abnormal blood vessel growth and leakage, causing vision problems or loss.
Anti-VEGF drugs work by inhibiting or blocking the activity of VEGF, thus helping to reduce the growth of abnormal blood vessels and fluid leakage within the eye. These drugs are administered directly into the eye using injections.
Global Anti-VEGT Drugs market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Oncology and Ophthalmology are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Anti-VEGT Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Anti-VEGT Drugs key manufacturers include Genentech (Roche), Regeneron Pharmaceuticals, Novartis, AstraZeneca, Bayer, Abbott, Santen, Pfizer and Sanofi, etc. Genentech (Roche), Regeneron Pharmaceuticals, Novartis are top 3 players and held % sales share in total in 2022.
Anti-VEGT Drugs can be divided into Tyrosine Kinase Inhibitors, Monoclonal Antibodies and Others,, etc. Tyrosine Kinase Inhibitors is the mainstream product in the market, accounting for % sales share globally in 2022.
Anti-VEGT Drugs is widely used in various fields, such as Oncology, Ophthalmology and Others,, etc. Oncology provides greatest supports to the Anti-VEGT Drugs industry development. In 2022, global % sales of Anti-VEGT Drugs went into Oncology filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Anti-VEGT Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Genentech (Roche)
Regeneron Pharmaceuticals
Novartis
AstraZeneca
Bayer
Abbott
Santen
Pfizer
Sanofi
Bristol-Myers Squibb
GlaxoSmithKline
Eli Lilly & Company
Chugai Pharma
Kanghong Pharmaceutical
Segment by Type
Tyrosine Kinase Inhibitors
Monoclonal Antibodies
Others
Oncology
Ophthalmology
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Anti-VEGT Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Anti-VEGT Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Anti-VEGT Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Anti-VEGT Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Anti-VEGT Drugs introduction, etc. Anti-VEGT Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Anti-VEGT Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Anti-VEGF drugs work by inhibiting or blocking the activity of VEGF, thus helping to reduce the growth of abnormal blood vessels and fluid leakage within the eye. These drugs are administered directly into the eye using injections.
Global Anti-VEGT Drugs market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Oncology and Ophthalmology are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Anti-VEGT Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Anti-VEGT Drugs key manufacturers include Genentech (Roche), Regeneron Pharmaceuticals, Novartis, AstraZeneca, Bayer, Abbott, Santen, Pfizer and Sanofi, etc. Genentech (Roche), Regeneron Pharmaceuticals, Novartis are top 3 players and held % sales share in total in 2022.
Anti-VEGT Drugs can be divided into Tyrosine Kinase Inhibitors, Monoclonal Antibodies and Others,, etc. Tyrosine Kinase Inhibitors is the mainstream product in the market, accounting for % sales share globally in 2022.
Anti-VEGT Drugs is widely used in various fields, such as Oncology, Ophthalmology and Others,, etc. Oncology provides greatest supports to the Anti-VEGT Drugs industry development. In 2022, global % sales of Anti-VEGT Drugs went into Oncology filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Anti-VEGT Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Genentech (Roche)
Regeneron Pharmaceuticals
Novartis
AstraZeneca
Bayer
Abbott
Santen
Pfizer
Sanofi
Bristol-Myers Squibb
GlaxoSmithKline
Eli Lilly & Company
Chugai Pharma
Kanghong Pharmaceutical
Segment by Type
Tyrosine Kinase Inhibitors
Monoclonal Antibodies
Others
Segment by Application
Oncology
Ophthalmology
Others
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Anti-VEGT Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Anti-VEGT Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Anti-VEGT Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Anti-VEGT Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Anti-VEGT Drugs introduction, etc. Anti-VEGT Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Anti-VEGT Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices